Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Airdoc Technology CoHKSE:02251 -2.89%64 Quick Ratio is 10.12 as of Dec. 2025, which is 10% below its 10-year median of 11.26. GuruFocus rates HKSE:02251 with a GF Score™ of 64/100 and a GF Value™ of HK$15.18 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Beijing Airdoc Technology Co ranks better than 95.9% on this metric.
Beijing Airdoc Technology Co has a quick ratio of 10.12. It generally indicates good short-term financial strength.
The historical rank and industry rank for Beijing Airdoc Technology Co's Quick Ratio or its related term are showing as below:
HKSE:02251'
s Quick Ratio Range Over the Past 10 Years
Min: 0.59 Med: 11.26 Max: 25.97
Current: 10.12
During the past 7 years, Beijing Airdoc Technology Co's highest Quick Ratio was 25.97. The lowest was 0.59. And the median was 11.26.
HKSE:02251's Quick Ratio is ranked better than 95.9% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 1.28
vs HKSE:02251: 10.12
Beijing Airdoc Technology Co (HKSE:02251) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Beijing Airdoc Technology Co Quick Ratio Related Terms
Beijing Airdoc Technology Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02251 vs VEEV, BTSG, TEM: Quick Ratio Comparison
For the Health Information Services subindustry, Beijing Airdoc Technology Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Airdoc Technology Co Quick Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Beijing Airdoc Technology Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Beijing Airdoc Technology Co's Quick Ratio falls into.
Beijing Airdoc Technology Co Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Airdoc Technology Co (HKSE:02251) has a Quick Ratio of 10.12 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Beijing Airdoc Technology Co and its competitors. This is 10% below median its historical median of 11.26. Over the past decade, Beijing Airdoc Technology Co's Quick Ratio has ranged from 0.59 to 25.97. According to the industry distribution chart, Beijing Airdoc Technology Co ranks #28 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 4.1%.
Is Beijing Airdoc Technology Co's Quick Ratio too high?
Beijing Airdoc Technology Co's current Quick Ratio of 10.12 is 10% below median its 10-year median of 11.26. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 25.97. The Healthcare Providers & Services industry median Quick Ratio is 1.28. Beijing Airdoc Technology Co's value of 10.12 is 690.6% above this industry median. Based on the distribution chart, Beijing Airdoc Technology Co ranks #28 out of 683 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Airdoc Technology Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Airdoc Technology Co's Quick Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Beijing Airdoc Technology Co ranks #28 out of 683 companies for Quick Ratio. This places Beijing Airdoc Technology Co in the top 4% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.28. Beijing Airdoc Technology Co's value of 10.12 is 690.6% above this benchmark. Historically, Beijing Airdoc Technology Co's own Quick Ratio has ranged from 0.59 to 25.97 over the past decade. While the company's 10-year median is 11.26 vs. the industry median of 1.28, Beijing Airdoc Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Healthcare Providers & Services company?
The median Quick Ratio among Healthcare Providers & Services companies is 1.28, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Airdoc Technology Co's current Quick Ratio of 10.12 is 690.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Beijing Airdoc Technology Co and its competitors. For the Healthcare Providers & Services industry, the median Quick Ratio is 1.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Airdoc Technology Co's current Quick Ratio is 10.12, which is 10% below median its own 10-year median of 11.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Airdoc Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Airdoc Technology Co (HKSE:02251) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$15.18, compared to a current price of HK$7.90 — trading 48% below its estimated fair value. The current Quick Ratio is 10.12, which is 10% below median its 10-year median of 11.26 and 690.6% above the Healthcare Providers & Services industry median of 1.28. Beijing Airdoc Technology Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Beijing Airdoc Technology Co (HKSE:02251), the current Quick Ratio is 10.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Airdoc Technology Co (HKSE:02251) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Airdoc Technology Co stock appears to be undervalued.
The current stock price of HK$7.90 is trading 48% below its estimated GF Value™ of HK$15.18.
GuruFocus considers Beijing Airdoc Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02251:
Quick Ratio: 10.12 (10% below median its 10-year median of 11.26)
GF Value™: HK$15.18 vs. price of HK$7.90 (48% below fair value)
Industry Position: 690.6% above the Healthcare Providers & Services median (#28 of 683)
No single metric tells the full story. See the HKSE:02251 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue from the provision of AI-based software solutions, sales of hardware devices, and other services. Geographically, the company generates the majority of its revenue from Mainland China.
64GF Score
Get the complete analysis for HKSE:02251
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02251 has been successfully added to your 
